Dyrk1a gene dosage in glutamatergic neurons has key effects in cognitive deficits observed in mouse models of MRD7 and Down syndrome.
Perturbation of the excitation/inhibition (E/I) balance leads to neurodevelopmental diseases including to autism spectrum disorders, intellectual disability, and epilepsy. Loss-of-function mutations in the DYRK1A gene, located on human chromosome 21 (Hsa21,) lead to an intellectual disability syndro...
Guardado en:
Autores principales: | Véronique Brault, Thu Lan Nguyen, Javier Flores-Gutiérrez, Giovanni Iacono, Marie-Christine Birling, Valérie Lalanne, Hamid Meziane, Antigoni Manousopoulou, Guillaume Pavlovic, Loïc Lindner, Mohammed Selloum, Tania Sorg, Eugene Yu, Spiros D Garbis, Yann Hérault |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d01eb288fea740cd83a75fa843e3f2c8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
<i>Dyrk1a</i> from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome
por: Helin Atas-Ozcan, et al.
Publicado: (2021) -
ACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING
por: Aleksandra Palladina, et al.
Publicado: (2021) -
Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)
por: Amirhossein Kazemian, et al.
Publicado: (2021) -
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
por: Yan Peng, et al.
Publicado: (2021) -
Novel glutamatergic drugs for the treatment of mood disorders
por: Murrough JW, et al.
Publicado: (2013)